Quantum-Si (NASDAQ:QSI) CEO Jeffrey Alan Hawkins Sells 11,311 Shares of Stock

Quantum-Si Incorporated (NASDAQ:QSI) CEO Jeffrey Alan Hawkins sold 11,311 shares of the firm’s stock in a transaction on Tuesday, June 23rd. The stock was sold at an average price of $0.90, for a total value of $10,179.90. Following the sale, the chief executive officer owned 3,669,802 shares in the company, valued at $3,302,821.80. This trade represents a 0.31% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Jeffrey Alan Hawkins also recently made the following trade(s):

• On Monday, June 22nd, Jeffrey Alan Hawkins sold 11,310 shares of Quantum-Si stock. The shares were sold at an average price of $0.96, for a total value of $10,857.60.
• On Monday, April 20th, Jeffrey Alan Hawkins sold 83,712 shares of Quantum-Si stock. The shares were sold at an average price of $1.01, for a total value of $84,549.12.

Quantum-Si Trading Down 6.0%

NASDAQ QSI opened at $0.83 on Thursday. The business’s 50-day moving average price is $0.99 and its 200 day moving average price is $1.04. Quantum-Si Incorporated has a twelve month low of $0.69 and a twelve month high of $3.10. The company has a market capitalization of $180.13 million, a PE ratio of -1.62 and a beta of 3.18.

Quantum-Si (NASDAQ:QSI) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.10) EPS for the quarter, beating the consensus estimate of ($0.12) by $0.02. The company had revenue of $0.26 million during the quarter, compared to analysts’ expectations of $0.30 million. Quantum-Si had a negative return on equity of 47.35% and a negative net margin of 5,605.88%. Equities analysts predict that Quantum-Si Incorporated will post -0.49 EPS for the current year.

Hedge Funds Weigh In On Quantum-Si

Several hedge funds and other institutional investors have recently modified their holdings of the company. Prudential Financial Inc. purchased a new stake in shares of Quantum-Si during the 2nd quarter worth about $25,000. Curbstone Financial Management Corp acquired a new position in Quantum-Si during the fourth quarter valued at approximately $26,000. Leonteq Securities AG acquired a new position in Quantum-Si during the fourth quarter valued at approximately $28,000. Cerity Partners LLC purchased a new stake in Quantum-Si during the second quarter worth approximately $29,000. Finally, Hollencrest Capital Management increased its position in shares of Quantum-Si by 301.1% in the first quarter. Hollencrest Capital Management now owns 40,111 shares of the company’s stock worth $31,000 after acquiring an additional 30,111 shares in the last quarter. 39.90% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts recently commented on the stock. Canaccord Genuity Group dropped their price target on shares of Quantum-Si from $1.50 to $1.00 and set a “hold” rating for the company in a research report on Wednesday, March 4th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Quantum-Si in a report on Friday, March 27th. One research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Quantum-Si currently has a consensus rating of “Reduce” and an average price target of $1.00.

Quantum-Si Company Profile

Quantum-Si Inc is a life sciences instrumentation company headquartered in Guilford, Connecticut, developing next-generation proteomics solutions based on semiconductor sequencing technology. The company’s core offering centers on a proprietary single-molecule protein sequencing platform that uses a silicon-based sensor chip to convert protein data into digital signals. This approach is designed to deliver high sensitivity, single-amino-acid resolution and deep proteome coverage while potentially reducing cost and complexity compared to traditional mass spectrometry methods.

Quantum-Si’s product roadmap includes the development and commercialization of an integrated system comprising instruments, consumable reagents and proprietary data analysis software.